Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection.

Staphylococcus aureus bacteriophage therapy cell surface receptor prosthetic joint infection transaminitis

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
04 May 2022
Historique:
received: 31 03 2022
revised: 27 04 2022
accepted: 02 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Prosthetic joint infections are a devastating complication of joint replacement surgery. Consequently, novel therapeutics are needed to thwart the significant morbidity and enormous financial ramifications that are associated with conventional treatments. One such promising adjuvant therapeutic is bacteriophage therapy given its antibiofilm activity and its ability to self-replicate. Herein we discuss the case of a 70-year-old female who had a recalcitrant MRSA prosthetic knee and femoral lateral plate infection who was successfully treated with adjuvant bacteriophage therapy. Moreover, this case discusses the importance of propagating bacteriophage therapeutics on bacteria that are devoid of toxins and the need to ensure bacteriophage activity to all bacterial morphologies. Overall, this case reinforces the potential benefit of using personalized bacteriophage therapy for recalcitrant prosthetic joint infections, but more translational research is needed to thereby devise effective, reproducible clinical trials.

Identifiants

pubmed: 35625260
pii: antibiotics11050616
doi: 10.3390/antibiotics11050616
pmc: PMC9137795
pii:
doi:

Types de publication

Case Reports

Langues

eng

Références

Front Med (Lausanne). 2021 May 05;8:569159
pubmed: 34026768
Pharmaceuticals (Basel). 2021 Mar 08;14(3):
pubmed: 33800146
J Arthroplasty. 2021 May;36(5):1484-1489.e3
pubmed: 33422392
PLoS One. 2020 Apr 17;15(4):e0231791
pubmed: 32302361
Int J Infect Dis. 2022 Jun;119:44-46
pubmed: 35331932
EFORT Open Rev. 2019 Jul 29;4(7):482-494
pubmed: 31423332
Sci Rep. 2019 Mar 1;9(1):3212
pubmed: 30824758
Viruses. 2019 Sep 23;11(10):
pubmed: 31548497
Infect Drug Resist. 2021 Dec 23;14:5629-5637
pubmed: 34992389
J Arthroplasty. 2020 Jun;35(6):1696-1702.e1
pubmed: 32192834
Open Forum Infect Dis. 2021 May 26;8(6):ofab277
pubmed: 34159220
Infection. 2022 Feb;50(1):281-283
pubmed: 34328615
Expert Rev Anti Infect Ther. 2018 Jan;16(1):51-65
pubmed: 29235402
J Bone Miner Res. 2017 May;32(5):985-990
pubmed: 27933662
Curr Pharm Des. 2015;21(1):85-99
pubmed: 25189866
J Arthroplasty. 2019 Jul;34(7S):S337-S342
pubmed: 30642705
Clin Infect Dis. 2013 Jan;56(1):e1-e25
pubmed: 23223583
Front Med (Lausanne). 2020 Nov 16;7:570572
pubmed: 33304911
Lancet Infect Dis. 2019 Jan;19(1):35-45
pubmed: 30292481
Appl Microbiol Biotechnol. 2019 Jun;103(11):4279-4289
pubmed: 30997551

Auteurs

James B Doub (JB)

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Vincent Y Ng (VY)

Department of Orthopedic Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Myounghee Lee (M)

Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD 21201, USA.

Andrew Chi (A)

Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD 21201, USA.

Alina Lee (A)

Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520, USA.
Yale Center for Phage Biology & Therapy, Yale University, New Haven, CT 06520, USA.

Silvia Würstle (S)

Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520, USA.
Yale Center for Phage Biology & Therapy, Yale University, New Haven, CT 06520, USA.

Benjamin Chan (B)

Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520, USA.
Yale Center for Phage Biology & Therapy, Yale University, New Haven, CT 06520, USA.

Classifications MeSH